TOP NEWS: US FDA Grants Breakthrough Status To AstraZeneca Treatment
LONDON (Alliance News) - AstraZeneca PLC on Monday said its drug selumetinib has been granted a breakthrough therapy designation in the US for neurofibromatosis type 1.Neurofibromatosis 1 1
